title: Pharmacological profiles and results of clinical studies of denosumab (RANMARK®), a human anti-RANKL antibody.
authors.affiliation: majima.shuji.bs@daiichisankyo.co.jp
authors.forename: Shuji
authors.initials: S
authors.lastname: Majima
authors.forename: Teiji
authors.initials: T
authors.lastname: Wada
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Ikeda
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use*; D000069448:Denosumab; D004311:Double-Blind Method; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D053245:RANK Ligand / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab